Kirsten Axelsen

Featured in: Favicon

post-gazette.com Favicon

washingtonexaminer.com Favicon

morningconsult.com Favicon

aei.org

wvgazettemail.com Favicon

news-journal.com Favicon

biospace.com Favicon

itif.org

myjournalcourier.com Favicon

pm360online.com + 2 more

Articles

Medical innovation Archives

1 month ago | aei.org | James Pethokoukis |Sally Satel |Kirsten Axelsen |Peter Pitts

Post Washington Should Fund More Potential Science Miracles Article Up Wing/Down Wing #43 Article Up Wing/Down Wing #42 Article Up Wing/Down Wing #41 Article Up Wing/Down Wing #40 Article Up Wing/Down Wing #39 Article Up Wing/Down Wing #38 Article A Twist on the Notion That Big Ideas Are Getting Harder To Find Article Medical Schools’ Botched Pass-Fail Experiment Post Seizing Intellectual Property for Medicines Is Not a Path to Prosperity Article The Future of Weight Loss Drugs: A Quick Q&A...
Canadian Election Recap: Results and Foreign Policy Implications

2 months ago | aei.org | Henry Olsen |With Colin Dueck |Colin Dueck |Kirsten Axelsen

While known to be traditionally predictable, Canada’s recent snap federal election has been anything but. Early this January, polling showed that the Liberal Party of Canada was on track to suffer one of the largest political defeats in Canadian history, induced by public dissatisfaction with former Prime Minister Justin Trudeau’s administration. However, the months preceding this election showed a surge in Liberal support driven by national pride and economic uncertainty.
Don’t Import Bad Policy Ideas on Drug Pricing

Nov 13, 2024 | aei.org | Kirsten Axelsen

The U.S. is the most important market for drug development. The country has rapid scientific reviews and drug approvals, and typically a quick and predictable pathway to reimbursement. It is unfortunate, then, that our policymakers are borrowing ideas from countries that have destroyed incentives to invest in their life sciences economies and reduced their citizens’ access to life-changing treatments. If we borrow these bad ideas, we will also borrow their bad outcomes.
Evidence to Inform Biopharmaceutical Policy: A Call for Research on the Impact of Public Policies on Investment in Drug Development

Oct 28, 2024 | itif.org | Sandra Barbosu |Kirsten Axelsen |Stephen Ezell

KEY TAKEAWAYSThere is a pressing need for updated, robust evidence to inform biopharmaceutical policy. This need is especially urgent in light of recent initiatives such as the Inflation Reduction Act (IRA), which instituted price-setting provisions that would lead to reduced R&D investment and a large decrease in new drugs developed.
Evidence-Based Biopharmaceutical Policymaking: Symposium Report

Oct 23, 2024 | itif.org | Kirsten Axelsen |Sandra Barbosu |Stephen Ezell

The Information Technology and Innovation Foundation (ITIF) convened an expert symposium on October 10, 2024, to discuss the evidence that is currently available to assess financial returns from clinical development of biopharmaceuticals, and to consider related questions such as how investors measure financial returns, how drug development has evolved in the past 10 years, what kind of information is most useful in guiding biopharmaceutical policy, and what factors drive further innovation...
Risks to Clinical Development andAccess to Medicines

Sep 18, 2024 | aei.org | Kirsten Axelsen

Kirsten Axelsen recently testified before the Senate Finance Committee’s hearing Lower Health Care Costs for Americans: Understanding the Benefits of the Inflation Reduction Act. IntroductionChairman Wyden, Ranking Member Crapo, and members of the committee thank you for the opportunity to share my perspective on the Inflation Reduction Act’s (IRA) implications on medicines,costs and, by extension, on health and longevity.
Price Controls on Obesity Meds Is a Mistake

Aug 26, 2024 | aei.org | Kirsten Axelsen

The Inflation Reduction Act directs the federal government to set prices for ten drugs in Medicare, with a recent announcement highlighting how much the government will save as a result of this intervention. However, it remains to be seen if the people who rely on the Medicare Part D benefit for their medicines will see any savings materialize, as many of these drugs were already deeply discounted and preferred in formularies.
The Poorly Managed 340B Program Will Be Even Worse With The Inflation Reduction Act

Aug 13, 2024 | aei.org | Kirsten Axelsen

In U.S. healthcare, few policies are as poorly designed as the 340B drug discount program. But despite solid evidence that the program is poorly managed, the government has once again denied being accountable. Instead of fixing the program, they expanded it with the Inflation Reduction Act.
Changes to Medicare Could Make It More Expensive

Jul 8, 2024 | aei.org | Kirsten Axelsen

While much of the Inflation Reduction Act analysis has been focused on the newly established mandate for the federal government to set drug prices in Medicare, bringing down the price of medicines, the law also makes other changes to Medicare. It reduces federal subsidies to low-income and high-need people, putting more financial risk onto the health insurance companies and pharmacy benefit managers that offer drug plans and puts a limit on out-of-pocket spending for beneficiaries.
Turning Age 65 Should Not Be A Reason To Lose Medical Care

Jun 27, 2024 | aei.org | Kirsten Axelsen

Medicines that can help people with obesity lose weight face a distinct affordability challenge to affordability relative to other types of drugs. They are new and have pent-up demand, so they are perceived to be costly, which limits coverage in insurance plans. However, until they are covered, there is limited evidence of how much they cost or can save the health system.